Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy

Adams, 1998, Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu, Br. J. Cancer, 77, 1405, 10.1038/bjc.1998.233 Adams, 2005, Monoclonal antibody therapy of cancer, Nat. Biotechnol., 23, 1147, 10.1038/nbt1137 Amadori, 2004, Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A phase II study (AML‐15) of the EORTC and GIMEMA leukemia groups, Haematologica, 89, 950 Axworthy, 2000, Cure of human carcinoma xenografts by a single dose of pretargeted yttrium‐90 with negligible toxicity, Proc. Natl. Acad. Sci. USA, 97, 1802, 10.1073/pnas.97.4.1802 Bagshawe, 1995, Antibody‐directed enzyme prodrug therapy for cancer: Its theoretical basis and application, Mol. Med. Today, 1, 424, 10.1016/S1357-4310(95)90815-3 Baselga, 1998, Recombinant humanized anti‐HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res., 58, 2825 Baselga, 1996, Phase II study of weekly intravenous recombinant humanized anti‐p185HER2 monoclonal antibody in patients with HER2/neu‐overexpressing metastatic breast cancer, J. Clin. Oncol., 14, 737, 10.1200/JCO.1996.14.3.737 Baselga, 2000, Phase I studies of anti‐epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin, J. Clin. Oncol., 18, 904, 10.1200/JCO.2000.18.4.904 Bennett, 2005, Assessment of treatment‐related myelodysplastic syndromes and acute myeloid leukemia in patients with non‐Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, 105, 4576, 10.1182/blood-2004-12-4690 Berinstein, 1998, Association of serum rituximab (IDEC‐C2B8) concentration and anti‐tumor response in the treatment of recurrent low‐grade or follicular non‐Hodgkin's lymphoma, Ann. Oncol., 9, 995, 10.1023/A:1008416911099 Bielekova, 2004, Humanized anti‐CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta, Proc. Natl. Acad. Sci. USA, 101, 8705, 10.1073/pnas.0402653101 Bowen, 1997, Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia, Br. J. Haematol., 96, 617, 10.1046/j.1365-2141.1997.d01-2061.x Burke, 2003, Cytoreduction with iodine‐131‐anti‐CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias, Bone Marrow Transplant., 32, 549, 10.1038/sj.bmt.1704201 Carter, 2001, Improving the efficacy of antibody‐based cancer therapies, Nat. Rev. Cancer, 1, 118, 10.1038/35101072 Carter, 2005, Designer antibody‐based therapeutics for oncology, 147 Carter, 1992, Humanization of an anti‐p185HER2 antibody for human cancer therapy, Proc. Natl. Acad. Sci. USA, 89, 4285, 10.1073/pnas.89.10.4285 Cartron, 2002, Therapeutic activity of humanized anti‐CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754 Chester, 2004, Engineering antibodies for clinical applications in cancer, Tumor Biol., 25, 91, 10.1159/000077727 Chinn, 1999, Preclinical evaluation of 90Y‐labeled anti‐CD20 monoclonal antibody for treatment of non‐Hodgkin's lymphoma, Int. J. Oncol., 15, 1017 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti‐HER2 monoclonal antibody in women who have HER2‐overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639 Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma, N. Engl. J. Med., 346, 235, 10.1056/NEJMoa011795 Coles, 1999, Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis, Lancet, 354, 1691, 10.1016/S0140-6736(99)02429-0 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan‐refractory metastatic colorectal cancer, N. Engl. J. Med., 351, 337, 10.1056/NEJMoa033025 Davies, 2004, Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B‐cell non‐Hodgkin's lymphoma, J. Clin. Oncol., 22, 1469, 10.1200/JCO.2004.06.055 Davis, 2000, Rituximab anti‐CD20 monoclonal antibody therapy in non‐Hodgkin's lymphoma: Safety and efficacy of re‐treatment, J. Clin. Oncol., 18, 3135, 10.1200/JCO.2000.18.17.3135 Davis, 2004, The radioisotope contributes significantly to the activity of radioimmunotherapy, Clin. Cancer Res., 10, 7792, 10.1158/1078-0432.CCR-04-0756 Denny, 2004, Tumor‐activated prodrugs—a new approach to cancer therapy, Cancer Invest., 22, 604, 10.1081/CNV-200027148 De Santes, 1992, Radiolabeled antibody targeting of the HER‐2/neu oncoprotein, Cancer Res., 52, 1916 Di Gaetano, 2003, Complement activation determines the therapeutic activity of rituximab in vivo, J. Immunol., 171, 1581, 10.4049/jimmunol.171.3.1581 Dinndorf, 1986, Expression of normal myeloid‐associated antigens by acute leukemia cells, Blood, 67, 1048, 10.1182/blood.V67.4.1048.1048 Dong, 2002, Tumor‐associated B7‐H1 promotes T‐cell apoptosis: A potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm0902-1039c Dowell, 2001, Pharmacokinetics of gemtuzumab ozogamicin, an antibody‐targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse, J. Clin. Pharmacol., 41, 1206, 10.1177/00912700122012751 Dowsett, 2003, Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres, J. Pathol., 199, 418, 10.1002/path.1313 Dranoff, 2004, Cytokines in cancer pathogenesis and cancer therapy, Nat. Rev. Cancer, 4, 11, 10.1038/nrc1252 Dranoff, 2005, CTLA‐4 blockade: Unveiling immune regulation, J. Clin. Oncol., 23, 662, 10.1200/JCO.2005.09.923 Dupont, 2005, Safety and pharmacokinetics of intravenous VEGF trap in a Phase I clinical trial of patients with advanced solid tumors, J. Clin. Oncol., 23, 3029, 10.1200/jco.2005.23.16_suppl.3029 Ehrlich, 1956, On immunity with special reference to cell life: Croonian lecture, Vol. II, 148 Essand, 1995, Radioimmunotherapy of prostatic adenocarcinomas: Effects of 131I‐labelled E4 antibodies on cells at different depth in DU 145 spheroids, Int. J. Cancer, 63, 387, 10.1002/ijc.2910630315 Fan, 1993, Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti‐epidermal growth factor receptor monoclonal antibodies, Cancer Res., 53, 4322 Flavell, 2002, Transforming growth factor‐B in T cell biology, Nat. Rev. Immunol., 2, 46, 10.1038/nri704 Freeman, 2000, Engagement of the PD‐1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192, 1027, 10.1084/jem.192.7.1027 Freeman, 1995, Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules, Blood, 85, 2005, 10.1182/blood.V85.8.2005.bloodjournal8582005 Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res., 65, 671, 10.1158/0008-5472.671.65.3 Goldstein, 1986, An overview of Orthoclone OKT3 transplantation proceedings, 18, 927 Goldstein, 1995, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin. Cancer Res., 1, 1311 Gordon, 2001, Phase I safety and pharmacokinetic study of recombinant human anti‐vascular endothelial growth factor in patients with advanced cancer, J. Clin. Oncol., 19, 843, 10.1200/JCO.2001.19.3.843 Gorelik, 2001, Immune‐mediated eradication of tumors through the blockade of transforming growth factor‐beta signaling in T cells, Nat. Med., 7, 1118, 10.1038/nm1001-1118 Grazette, 2004, Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin‐induced cardiomyopathy, J. Am. Coll. Cardiol., 44, 2231, 10.1016/j.jacc.2004.08.066 Gura, 2002, Therapeutic antibodies: Magic bullets hit the target, Nature, 417, 584, 10.1038/417584a Hale, 1983, Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement, Blood, 62, 873, 10.1182/blood.V62.4.873.873 Hale, 1988, Remission induction in non‐Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH‐1H, Lancet, 2, 1394, 10.1016/S0140-6736(88)90588-0 Hamann, 2002, Gemtuzumab ozogamicin, a potent and selective anti‐CD33 antibody‐calicheamicin conjugate for treatment of acute myeloid leukemia, Bioconjug. Chem., 13, 47, 10.1021/bc010021y Herbst, 2005, Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck, J. Clin. Oncol., 23, 5578, 10.1200/JCO.2005.07.120 Herbst, 2001, IMC‐C225, an anti‐epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer, Expert Opin. Biol. Ther., 1, 719, 10.1517/14712598.1.4.719 Hericourt, 1895, Physologie pathologique'—de la serotherapie dans la traitement du cancer, C.R. Hebd. Seanc. Acad. Sci., 121, 567 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol., 23, 1011, 10.1200/JCO.2005.06.081 Hinton, 2004, Engineered human IgG antibodies with longer serum half‐lives in primates, J. Biol. Chem., 279, 6213, 10.1074/jbc.C300470200 Hodi, 2003, Biologic activity of cytotoxic T lymphocyte‐associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proc. Natl. Acad. Sci. USA, 100, 4712, 10.1073/pnas.0830997100 Hoeben, 2004, Vascular endothelial growth factor and angiogenesis, Pharmacol. Rev., 56, 549, 10.1124/pr.56.4.3 Horning, 2005, Efficacy and safety of tositumomab and iodine‐131 tositumomab (Bexxar) in B‐cell lymphoma, progressive after rituximab, J. Clin. Oncol., 23, 712, 10.1200/JCO.2005.07.040 Hudson, 2003, Engineered antibodies, Nat. Med., 9, 129, 10.1038/nm0103-129 Hurwitz, 2000, Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA‐4 blockade, Cancer Res., 60, 2444 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 350, 2335, 10.1056/NEJMoa032691 Isaacs, 1992, Humanised monoclonal antibody therapy for rheumatoid arthritis, Lancet, 340, 748, 10.1016/0140-6736(92)92294-P Iwai, 2002, Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade, Proc. Natl. Acad. Sci. USA, 99, 12293, 10.1073/pnas.192461099 Izumi, 2002, Tumour biology: Herceptin acts as an anti‐angiogenic cocktail, Nature, 416, 279, 10.1038/416279b Jain, 2001, Delivery of molecular and cellular medicine to solid tumors, Adv. Drug Deliv. Rev., 46, 149, 10.1016/S0169-409X(00)00131-9 Junghans, 1996, The protection receptor for IgG catabolism is the beta2‐microglobulin‐containing neonatal intestinal transport receptor, Proc. Natl. Acad. Sci. USA, 93, 5512, 10.1073/pnas.93.11.5512 Jurcic, 2002, Targeted alpha particle immunotherapy for myeloid leukemia, Blood, 100, 1233, 10.1182/blood.V100.4.1233.h81602001233_1233_1239 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J. Clin. Oncol., 21, 60, 10.1200/JCO.2003.10.066 Kaminski, 1996, Iodine‐131‐anti‐B1 radioimmunotherapy for B‐cell lymphoma, J. Clin. Oncol., 14, 1974, 10.1200/JCO.1996.14.7.1974 Kaminski, 2005, 131I‐tositumomab therapy as initial treatment for follicular lymphoma, N. Engl. J. Med., 352, 441, 10.1056/NEJMoa041511 Keating, 2002, Therapeutic role of alemtuzumab (Campath‐1H) in patients who have failed fludarabine: Results of a large international study, Blood, 99, 3554, 10.1182/blood.V99.10.3554 Kell, 2003, A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia, Blood, 102, 4277, 10.1182/blood-2003-05-1620 Kennedy, 2002, Campath‐1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia, Blood, 99, 2245, 10.1182/blood.V99.6.2245 Khorana, 2001, A phase II multicenter study of CAMPATH‐1H antibody in previously treated patients with nonbulky non‐Hodgkin's lymphoma, Leuk. Lymphoma, 41, 77, 10.3109/10428190109057956 Kim, 1993, Inhibition of vascular endothelial growth factor‐induced angiogenesis suppresses tumour growth in vivo, Nature, 362, 841, 10.1038/362841a0 Koene, 1997, Fc gammaRIIIa‐158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa‐48L/R/H phenotype, Blood, 90, 1109, 10.1182/blood.V90.3.1109 Köhler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Krackhardt, 2002, Identification of tumor‐associated antigens in chronic lymphocytic leukemia by SEREX, Blood, 100, 2123, 10.1182/blood-2002-02-0513 Kreitman, 2003, Recombinant toxins for the treatment of cancer, Curr. Opin. Mol. Ther., 5, 44 Kreitman, 2000, Phase I trial of recombinant immunotoxin anti‐Tac(Fv)‐PE38 (LMB‐2) in patients with hematologic malignancies, J. Clin. Oncol., 18, 1622, 10.1200/JCO.2000.18.8.1622 Kreitman, 2001, Efficacy of the anti‐CD22 recombinant immunotoxin BL22 in chemotherapy‐resistant hairy‐cell leukemia, N. Engl. J. Med., 345, 241, 10.1056/NEJM200107263450402 Ku, 2000, Control of homeostasis of CD8+ memory T cells by opposing cytokines, Science, 288, 675, 10.1126/science.288.5466.675 Kwon, 1999, Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4) blockade immunotherapy, Proc. Natl. Acad. Sci. USA, 96, 15074, 10.1073/pnas.96.26.15074 Larson, 2005, Final report of the efficacy and safety of gemtuzumab ozogamicin (mylotarg) in patients with CD33 positive acute myloid leukemia in first recurrence, Cancer, 104, 1442, 10.1002/cncr.21326 Laurenti, 2004, Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir, Haematologica, 89, 1248 Leach, 1996, Enhancement of antitumor immunity by CTLA‐4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Lee, 2000, Anti‐vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions, Cancer Res., 60, 5565 Lenardo, 1996, Fas and the art of lymphocyte maintenance, J. Exp. Med., 183, 721, 10.1084/jem.183.3.721 Lewis, 1993, Differential responses of human tumor cell lines to anti‐p185HER2 monoclonal antibodies, Cancer Immunol. Immunother., 37, 255, 10.1007/BF01518520 Linenberger, 2005, CD33‐directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance, Leukemia, 19, 176, 10.1038/sj.leu.2403598 Linenberger, 2001, Multidrug‐resistance phenotype and clinical responses to gemtuzumab ozogamicin, Blood, 98, 988, 10.1182/blood.V98.4.988 Lode, 2000, Targeted cytokines for cancer immunotherapy, Immunol. Res., 21, 279, 10.1385/IR:21:2-3:279 Lowenberg, 1999, Acute myeloid leukemia, N. Engl. J. Med., 341, 1051, 10.1056/NEJM199909303411407 Lozanski, 2004, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood, 103, 3278, 10.1182/blood-2003-10-3729 Lundin, 1998, CAMPATH‐1H monoclonal antibody in therapy for previously treated low‐grade non‐Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH‐1H Treatment in Low‐Grade Non‐Hodgkin's Lymphoma, J. Clin. Oncol., 16, 3257, 10.1200/JCO.1998.16.10.3257 Maloney, 1994, Phase I clinical trial using escalating single‐dose infusion of chimeric anti‐CD20 monoclonal antibody (IDEC‐C2B8) in patients with recurrent B‐cell lymphoma, Blood, 84, 2457, 10.1182/blood.V84.8.2457.2457 Maloney, 1997, IDEC‐C2B8: Results of a phase I multiple‐dose trial in patients with relapsed non‐Hodgkin's lymphoma, J. Clin. Oncol., 15, 3266, 10.1200/JCO.1997.15.10.3266 Margolin, 2001, Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long‐term safety data, J. Clin. Oncol., 19, 851, 10.1200/JCO.2001.19.3.851 Marks‐Konczalik, 2000, IL‐2‐induced activation‐induced cell death is inhibited in IL‐15 transgenic mice, Proc. Natl. Acad. Sci. USA, 97, 11445, 10.1073/pnas.200363097 McLaughlin, 1998, Rituximab chimeric anti‐CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four‐dose treatment program, J. Clin. Oncol., 16, 2825, 10.1200/JCO.1998.16.8.2825 Mendelsohn, 1997, Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy, Clin. Cancer Res., 3, 2703 Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082 Milenic, 2004, Antibody‐targeted radiation cancer therapy, Nat. Rev. Drug. Discov., 3, 488, 10.1038/nrd1413 Miller, 1982, Treatment of B‐cell lymphoma with monoclonal anti‐idiotype antibody, N. Engl. J. Med., 306, 517, 10.1056/NEJM198203043060906 Mir, 2000, Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells, Blood, 96, 4307, 10.1182/blood.V96.13.4307 Morris, 2000, Advances in interleukin 2 receptor targeted treatment, Ann. Rheum. Dis., 59, i109, 10.1136/ard.59.suppl_1.i109 Mulford, 2005, The promise of targeted (alpha)‐particle therapy, J. Nucl. Med., 46, 199S Nadler, 1981, A unique cell surface antigen identifying lymphoid malignancies of B cell origin, J. Clin. Invest., 67, 134, 10.1172/JCI110005 Naito, 2000, Calicheamicin‐conjugated humanized anti‐CD33 monoclonal antibody (gemtuzumab zogamicin, CMA‐676) shows cytocidal effect on CD33‐positive leukemia cell lines, but is inactive on P‐glycoprotein‐expressing sublines, Leukemia, 14, 1436, 10.1038/sj.leu.2401851 Nimmerjahn, 2005, FcgammaRIV: A novel FcR with distinct IgG subclass specificity, Immunity, 23, 41, 10.1016/j.immuni.2005.05.010 Nussenblatt, 1999, Treatment of noninfectious intermediate and posterior uveitis with the humanized anti‐Tac mAb: A phase I/II clinical trial, Proc. Natl. Acad. Sci. USA, 96, 7462, 10.1073/pnas.96.13.7462 Olafsen, 2004, Characterization of engineered anti‐p185HER‐2 (scFv‐CH3)2 antibody fragments for tumor targeting, Protein Eng. Des. Sel., 17, 315, 10.1093/protein/gzh040 Olsen, 2001, Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T‐cell lymphoma, J. Clin. Oncol., 19, 376, 10.1200/JCO.2001.19.2.376 Osterborg, 1997, Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH‐1H Treatment in Chronic Lymphocytic Leukemia, J. Clin. Oncol., 15, 1567, 10.1200/JCO.1997.15.4.1567 Osterborg, 1996, Humanized CD52 monoclonal antibody Campath‐1H as first‐line treatment in chronic lymphocytic leukaemia, Br. J. Haematol., 93, 151, 10.1046/j.1365-2141.1996.450989.x Pegram, 1999, Inhibitory effects of combinations of HER‐2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, 2241, 10.1038/sj.onc.1202526 Piro, 1999, Extended Rituximab (anti‐CD20 monoclonal antibody) therapy for relapsed or refractory low‐grade or follicular non‐Hodgkin's lymphoma, Ann. Oncol., 10, 655, 10.1023/A:1008389119525 Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte‐associated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci. USA, 100, 8372, 10.1073/pnas.1533209100 Press, 2001, A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20‐expressing lymphoma xenografts, Blood, 98, 2535, 10.1182/blood.V98.8.2535 Press, 1995, Phase II trial of 131I‐B1 (anti‐CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet, 346, 336, 10.1016/S0140-6736(95)92225-3 Press, 1996, Comparative metabolism and retention of iodine‐125, yttrium‐90, and indium‐111 radioimmunoconjugates by cancer cells, Cancer Res., 56, 2123 Presta, 1997, Humanization of an anti‐vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res., 57, 4593 Queen, 1989, A humanized antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci. USA, 86, 10029, 10.1073/pnas.86.24.10029 Rai, 2002, Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine, J. Clin. Oncol., 20, 3891, 10.1200/JCO.2002.06.119 Ravetch, 2000, Immune inhibitory receptors, Science, 290, 84, 10.1126/science.290.5489.84 Rebello, 2001, Pharmacokinetics of CAMPATH‐1H in BMT patients, Cytotherapy, 3, 261, 10.1080/146532401317070899 Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, 435, 10.1182/blood.V83.2.435.435 Riechmann, 1988, Reshaping human antibodies for therapy, Nature, 332, 323, 10.1038/332323a0 Riethmuller, 1998, Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven‐year outcome of a multicenter randomized trial, J. Clin. Oncol., 16, 1788, 10.1200/JCO.1998.16.5.1788 Robert, 2001, Phase I study of anti‐epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer, J. Clin. Oncol., 19, 3234, 10.1200/JCO.2001.19.13.3234 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER‐2 positive breast cancer, N. Engl. J. Med., 353, 1673, 10.1056/NEJMoa052122 Rosenberg, 1994, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high‐dose bolus interleukin‐2, JAMA, 271, 907, 10.1001/jama.1994.03510360033032 Sakaguchi, 2004, Naturally arising CD4+ regulatory T cells for immunologic self‐tolerance and negative control of immune responses, Annu. Rev. Immunol., 22, 531, 10.1146/annurev.immunol.21.120601.141122 Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J. Clin. Oncol., 22, 1201, 10.1200/JCO.2004.10.182 Schwartzentruber, 2003, Cancer regression induced by cytotoxic T‐lymphocytes associated antigen 4‐blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci. USA, 100, 8372, 10.1073/pnas.1533209100 Segal, 2001, Introduction: Bispecific antibodies, J. Immunol. Methods, 248, 1, 10.1016/S0022-1759(00)00338-0 Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J. Clin. Oncol., 20, 1215, 10.1200/JCO.20.5.1215 Shevach, 2000, Regulatory T cells in autoimmmunity, Annu. Rev. Immunol., 18, 423, 10.1146/annurev.immunol.18.1.423 Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200 Shimizu, 1999, Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity, J. Immunol., 163, 5211, 10.4049/jimmunol.163.10.5211 Shin, 2001, Epidermal growth factor receptor targeted therapy with C225 and cisplatin in patients with head and neck cancer, Clin. Cancer Res., 7, 1204 Shinkawa, 2003, The absence of fucose but not the presence of galactose or bisecting N‐acetylglucosamine of human IgG1 complex‐type oligosaccharides shows the critical role of enhancing antibody‐dependent cellular cytotoxicity, J. Biol. Chem., 278, 3466, 10.1074/jbc.M210665200 Sievers, 1999, Selective ablation of acute myeloid leukemia using antibody‐targeted chemotherapy: A phase I study of an anti‐CD33 calicheamicin immunoconjugate, Blood, 93, 3678, 10.1182/blood.V93.11.3678 Sievers, 2001, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33‐positive acute myeloid leukemia in first relapse, J. Clin. Oncol., 19, 3244, 10.1200/JCO.2001.19.13.3244 Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER‐2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Sliwkowski, 1999, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin. Oncol., 26, 60 Smith, 2003, Rituximab (monoclonal anti‐CD20 antibody): Mechanisms of action and resistance, Oncogene, 22, 7359, 10.1038/sj.onc.1206939 Stacy, 2005, Therapeutic MAbs: Saving lives and making billions, The Scientist, 19, 17 Staerz, 1985, Hybrid antibodies can target sites for attack by T cells, Nature, 314, 628, 10.1038/314628a0 Stashenko, 1981, Expression of cell surface markers after human B lymphocyte activation, Proc. Natl. Acad. Sci. USA, 78, 3848, 10.1073/pnas.78.6.3848 Sunada, 1986, Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation, Proc. Natl. Acad. Sci. USA, 83, 3825, 10.1073/pnas.83.11.3825 Sutmuller, 2001, Synergism of cytotoxic T lymphocyte‐associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses, J. Exp. Med., 194, 823, 10.1084/jem.194.6.823 Terabe, 2000, NKT cell‐mediated repression of tumor immunosurveillance by IL‐13 and the IL‐4R‐STAT6 pathway, Nat. Immunol., 1, 515, 10.1038/82771 Thornton, 2000, Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific, J. Immunol., 164, 183, 10.4049/jimmunol.164.1.183 Treumann, 1995, Primary structure of CD52, J. Biol. Chem., 270, 6088, 10.1074/jbc.270.11.6088 Tsimberidou, 2003, Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes, Cancer, 97, 1481, 10.1002/cncr.11239 Uppenkamp, 2002, Monoclonal antibody therapy with CAMPATH‐1H in patients with relapsed high‐ and low‐grade non‐Hodgkin's lymphomas: A multicenter phase I/II study, Ann. Hematol., 81, 26, 10.1007/s00277-001-0394-7 van der Velden, 2004, High CD33‐antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients, Leukemia, 18, 983, 10.1038/sj.leu.2403350 van Der Velden, 2001, Targeting of the CD33‐calicheamicin immunoconjugate Mylotarg (CMA‐676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells, Blood, 97, 3197, 10.1182/blood.V97.10.3197 Vincenti, 1998, Interleukin‐2‐receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group, N. Engl. J. Med., 338, 161, 10.1056/NEJM199801153380304 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first‐line treatment of HER2‐overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719 von Behring, 1890, The mechanism of immunity in animals to diphtheria and tetanus, 138 von Mehren, 2003, Monoclonal antibody therapy for cancer, Annu. Rev. Med., 54, 343, 10.1146/annurev.med.54.101601.152442 Vose, 2000, Multicenter phase II study of iodine‐131 tositumomab for chemotherapy‐relapsed/refractory low‐grade and transformed low‐grade B‐cell non‐Hodgkin's lymphomas, J. Clin. Oncol., 18, 1316, 10.1200/JCO.2000.18.6.1316 Wahl, 2005, Tositumomab and (131) I therapy in non‐Hodgkin's lymphoma, J. Nucl. Med., 46, 165 Waldmann, 1991, Monoclonal antibodies in diagnosis and therapy, Science, 252, 1657, 10.1126/science.2047874 Waldmann, 2003, ABCsv of radioisotopes used for radioimmunotherapy: Alpha‐ and beta‐emitters, Leuk. Lymphoma, 44, S107, 10.1080/10428190310001623685 Waldmann, 2003, Immunotherapy: Past, present and future, Nat. Med., 9, 269, 10.1038/nm0303-269 Waldmann, 1969, Metabolism of immunoglobulins, Prog. Allergy, 13, 1 Waldmann, 1993, The interleukin‐2 receptor: A target for monoclonal antibody treatment of human T‐cell lymphotropic I virus induced adult T‐cell leukemia, Blood, 82, 1701, 10.1182/blood.V82.6.1701.1701 Waldmann, 2001, Contrasting roles of IL‐2 and IL‐15 in the life and death of lymphocytes: Implications for immunotherapy, Immunity, 14, 105 Waldmann, 1995, Radioimmunotherapy of interleukin‐2R alpha expressing adult T‐cell leukemia with yttrium‐90‐labeled anti‐Tac, Blood, 86, 4063, 10.1182/blood.V86.11.4063.bloodjournal86114063 Weiden, 2000, Pretargeted radioimmunotherapy (PRIT) for treatment of non‐Hodgkin's lymphoma (NHL): Initial phase I/II study results, Cancer Biother. Radiopharm., 15, 15, 10.1089/cbr.2000.15.15 Weinblatt, 2003, Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial, Arthritis. Rheum., 48, 35, 10.1002/art.10697 Weng, 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J. Clin. Oncol., 21, 3940, 10.1200/JCO.2003.05.013 Wing, 1996, Mechanism of first‐dose cytokine‐release syndrome by CAMPATH 1‐H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA‐1) on NK cells, J. Clin. Invest., 98, 2819, 10.1172/JCI119110 Winter, 1991, Man made antibodies, Nature, 349, 293, 10.1038/349293a0 Wiseman, 2002, Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non‐Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial, Blood, 99, 4336, 10.1182/blood.V99.12.4336 Witzig, 1999, Phase I/II trial of IDEC‐Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B‐cell non‐Hodgkin's lymphoma, J. Clin. Oncol., 17, 3793, 10.1200/JCO.1999.17.12.3793 Witzig, 2002, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab‐refractory follicular non‐Hodgkin's lymphoma, J. Clin. Oncol., 20, 3262, 10.1200/JCO.2002.11.017 Witzig, 2002, Randomized controlled trial of yttrium‐90‐labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low‐grade, follicular, or transformed B‐cell non‐Hodgkin's lymphoma, J. Clin. Oncol., 20, 2453, 10.1200/JCO.2002.11.076 Witzig, 2003, Safety of yttrium‐90 ibritumomab tiuxetan radioimmunotherapy for relapsed low‐grade, follicular, or transformed non‐Hodgkin's lymphoma, J. Clin. Oncol., 21, 1263, 10.1200/JCO.2003.08.043 Yang, 2003, A randomized trial of bevacizumab, an anti‐vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med., 349, 427, 10.1056/NEJMoa021491 Zalutsky, 1990, Labeling monoclonal antibodies with halogen nuclides, Acta Radiol. Suppl., 374, 141 Zein, 1988, Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double‐stranded DNA site specifically, Science, 240, 1198, 10.1126/science.3240341 Zhang, 2002, Pretargeting radioimmunotherapy of a murine model of adult T‐cell leukemia with the alpha‐emitting radionuclide, bismuth 213, Blood, 100, 208, 10.1182/blood-2002-01-0107 Zhang, 2004, Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T‐cell leukemia, Cancer Res., 64, 5825, 10.1158/0008-5472.CAN-04-1088 Zhang, 1998, Potent and selective stimulation of memory‐phenotype CD8+ T cells in vivo by IL‐15, Immunity, 8, 591, 10.1016/S1074-7613(00)80564-6 Zhao, 2003, MTS‐conjugated‐antiactive caspase 3 antibodies inhibit actinomycin D‐induced apoptosis, Apoptosis, 8, 631, 10.1023/A:1026139627930